GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » The Joint Corp (NAS:JYNT) » Definitions » Cash, Cash Equivalents, Marketable Securities

The Joint (The Joint) Cash, Cash Equivalents, Marketable Securities : $18.7 Mil (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is The Joint Cash, Cash Equivalents, Marketable Securities?

The Joint's quarterly cash, cash equivalents, marketable securities increased from Sep. 2023 ($16.05 Mil) to Dec. 2023 ($18.15 Mil) and increased from Dec. 2023 ($18.15 Mil) to Mar. 2024 ($18.74 Mil).

The Joint's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($19.53 Mil) to Dec. 2022 ($9.75 Mil) but then increased from Dec. 2022 ($9.75 Mil) to Dec. 2023 ($18.15 Mil).


The Joint Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for The Joint's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Joint Cash, Cash Equivalents, Marketable Securities Chart

The Joint Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.46 20.55 19.53 9.75 18.15

The Joint Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.77 13.60 16.05 18.15 18.74

The Joint Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


The Joint  (NAS:JYNT) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


The Joint Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of The Joint's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


The Joint (The Joint) Business Description

Industry
Traded in Other Exchanges
N/A
Address
16767 North Perimeter Drive, Suite 110, Scottsdale, AZ, USA, 85260
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sale of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.
Executives
Bandera Partners Llc 10 percent owner 50 BROAD STREET, SUITE 1820, NEW YORK NY 10004
Peter D Holt officer: Chief Operating Officer 16767 N. PERIMETER DR., SUITE 240, SCOTTSDALE AZ 85260
Jake Singleton officer: Chief Financial Officer 16767 NORTH PERIMETER DRIVE, SUITE 240, SCOTTSDALE AZ 85260
Ronald V Davella director 2600 E SOUTHLAKE BLVD., STE 120-359, SOUTHLAKE TX 76092
Glenn J Krevlin 10 percent owner 600 FIFTH AVE, 11TH FL, NEW YORK NY 10020
Matthew E Rubel director 3231 SE SIXTH AVENUE, TOPEKA KS 66607
Gregory Bylinsky 10 percent owner C/O BANDERA PARTNERS LLC, 50 BROAD STREET, SUITE 1820, NEW YORK NY 10004
Jefferson Gramm 10 percent owner C/O BANDERA PARTNERS LLC, 50 BROAD STREET, SUITE 1820, NEW YORK NY 10004
Amos James H. Jr director 16767 N. PERIMETER DR., STE. 240, SCOTTSDALE AZ 85260
John P Meloun officer: Chief Financial Officer 16767 N. PERIMETER DR., STE. 240, SCOTTSDALE AZ 85260
Abe Hong director 16767 NORTH PERIMETER DRIVE, SUITE 240, SCOTTSDALE AZ 85260
Glenhill Advisors Llc 10 percent owner 600 FIFTH AVE, 11TH FL, NEW YORK NY 10020
Suzanne M Decker director 16767 NORTH PERIMETER DRIVE, SUITE 240, SCOTTSDALE AZ 85260
Bret Sanders director 16767 N. PERIMETER DR., STE. 240, SCOTTSDALE AZ 85260
David M Orwasher officer: President and COO 242 W 36TH ST, NEW YORK NY 10018